About the Phase 3 WAYPOINT Trial ... to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration ...

in the trial were consistent ... tezepelumab's potential as a new treatment for patients whose lives are disrupted by this debilitating disease." "The top-line results from our Phase 3 WAYPOINT ...

UCB and Biogen say their first phase 3 trial of their systemic lupus ... If it makes it to market, the drug could provide a much-needed new treatment for SLE, a chronic, autoimmune disease that ...

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations ... modelled peak sales for the new drug of around £3 billion a ...

Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its ... comprises the Phase II ...

WINT Enrolling SCAI Stage C participants in SEISMiC C trial, preparing for Phase 3 readiness Pennsylvania-based Windtree ...

The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a ...

“The impressive data from the WAYPOINT trial demonstrate tezepelumab’s potential as a new treatment for patients whose lives are disrupted by this debilitating disease.” “The top-line results from our ...

Charting, Price Performance, News & Related Contracts.

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Notably, the successful completion of the FDA End of Phase ... the drug’s favorable cardiac efficacy. This positions Altimmune advantageously against competitors, with no significant safety concerns.